Citations

Clear

13603 citation(s) found for "_, _".

Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025
Singh, Siddharth, Desai, Aakash , Goodwin, Shane W. , Kochhar, Gursimran , Jairath, V , Desai, Aakash

Mayo Clinic

Journal of Crohn’s and Colitis | October 22, 2025 | Volume: 19 | Issue: 10 | Pages: No page available

10.1093/ecco-jcc/jjaf186 | PMID 41134654 Get It

Abstract Background and Aims Seven new advanced therapies, belonging to three new classes, have been approved for the treatment of inflammatory bowel diseases (IBD) since 2021. We examined trends in utilization of advanced therapies in the USA since 2021. Methods Using de-identified electronic health record data from 71 US health systems, we examined quarterly trends in utilization of different advanced therapies in patients with ulcerative colitis and Crohn’s disease between 2021 and 2025, using interrupted time-series analysis utilizing Prais–Winsten regression. Results In 11 093 patients with ulcerative colitis treated with advanced therapies, we observed an increase in use of upadacitinib (12.1% in Q2/2025; P < .001, compared with first quarter of prescription), interleukin-23p19 (IL23p19) antagonists (5.5%; P = .03), and ustekinumab (9.5%; P = .04), decline in use of tumor necrosis factor (TNF) antagonists (34.5%; P = .003), and stable use of vedolizumab (33.6%; P = .17) and sphingosine-1 phosphate receptor modulators (1.6%; P = .28). In 15 951 patients with Crohn’s disease treated with advanced therapies, we observed an increase in use of IL23p19 antagonists (15.0% in Q1/2025; P = .003) and upadacitinib (5.9%; P < .001) and decline in use of TNF antagonists (50.2%; P = .001) and ustekinumab (13.5%; P < .001). Conclusions Contemporary trends in advanced therapy utilization in patients with IBD suggest an increased utilization of upadacitinib and anti-interleukins, accompanied by a decline in use of TNF antagonists in the USA.
#2139 Renal uric acid microcrystals drive hyperinflammation, cystogenesis and disease progression in ADPKD
Strubl, Sebastian , Holznecht, Nickolas J., Aceves, Brina A., Schimmel, Meg, Koestner, Stella, Grundmann, Franziska , Mueller, Roman-Ulrich, Antczak, Philipp , Torres, Jacob A. , Schimmel, Meg, Alkarkoukly, Samer , Harris, Peter C. , Mueller, Roman-Ulrich, Weimbs, Thomas

Mayo Clinic

Nephrology Dialysis Transplantation | October 22, 2025 | Volume: 40 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaf116.0167 Get It

Abstract Background and Aims Patients with ADPKD exhibit an increased prevalence of kidney stones with a significant overrepresentation of uric acid (UA) stones which has led to the previous suggestion that UA may be associated with disease progression in ADPKD. However, available results are controversial and the exact mechanism remains unknown. Since we have previously reported that calcium-based microcrystals worsen ADPKD disease progression we hypothesized that renal UA crystallization could affect PKD disease progression and aimed to investigate this in animal models of PKD and the AD(H)PKD registry at the University Hospital Cologne. Method WT and Pkd1+/− rats were supplemented with UA and the uricase inhibitor oxonic acid from 8 to 10 weeks of age to induce moderate hyperuricemia causing renal UA crystal deposition. This was followed by washout from 10 to 18 weeks to analyze crystal clearance. For additional treatment with the ketone beta-hydroxybutyrate (BHB) and alkaline Citrate, adult rats received a solution containing 2.1% BHB and 13.75 mM tripotassium citrate/16.75 mM citric acid in the drinking water from 14 to 18 weeks of age. Human data including eGFR, UA levels in serum, spot urine and 24-hour urine and urine pH were used from the AD(H)PKD study (Clinical Trials ID: NCT02497521) and analyzed using multivariable linear models. Results UA crystal deposition in Pkd1+/− rats led to significantly increased kidney growth, tubule dilation and UA crystal burden compared to UA-treated WT controls. Dilated tubules exhibited strong TLR-4 expression, NLRP3 activation, recruitment of peritubular macrophages and intraluminal neutrophils undergoing NETosis. Strikingly—although untreated heterozygous Pkd1+/− rats fail to develop a polycystic phenotype—UA-treated Pkd1+/− rats developed polycystic kidney disease after 8 weeks washout period with persistent activation of TLR4, NLRP3, pericystic macrophages and intracystic neutrophils. UA-treated WT rats displayed a normalization of renal tubules. Previously, we demonstrated that treatment with BHB and Citrate can ameliorate PKD disease progression. BHB has been reported to inhibit TLR4-NLRP3 signaling and citrate can prevent UA deposition due to urine alkalinization. Therefore, we induced UA crystal deposition in Pkd1+/− followed by 4 weeks of normal diet to allow crystal clearance, followed by treatment with BHB/Citrate in the drinking water. Remarkably, BHB/Citrate potently inhibited the progression to PKD in Pkd1+/− rats by ameliorating cyst growth, TLR4-NLRP3 activation, and macrophage and neutrophil recruitment. Translational analysis of UA stone forming parameters in the AD(H)PKD patient registry showed a correlation of serum and urine UA concentration with eGFR slope. However, significance of this association was lost after adjusting for eGFR, age and sex. In contrast, analysis of the Marshal lithogenic risk score which combines urine UA with urine pH to predict the risk for UA crystal/stone formation showed a significant and independent impact on eGFR slope. Conclusion Our results suggest that UA exposure is a sufficient environmental hit to induce cystogenesis in a heterozygous Pkd1 rat model. A heterozygous Pkd1 gene mutation as observed in ADPKD patients creates a hyperresponsive renal phenotype upon UA crystal formation leading to exaggerated tubule dilation, persistent inflammation, fibrosis and progression to PKD. Treatment with BHB/Citrate significantly reduces TLR4-NLRP3 activation and macrophage/ neutrophil recruitment leading to a significant amelioration of UA-induced cystogenesis. We conclude that UA crystal deposition could accelerate PKD disease progression by NLRP3-mediated and macrophage/neutrophil-based hyperinflammation. BHB/Citrate could not only prevent UA crystallization but ameliorate UA-associated kidney injury and ADPKD disease progression. Finally, the translational analysis in the AD(H)PKD patient registry suggest that, although not showing serum uric acid as independent risk factor, the lithogenic risk- largely driven by the combination of urine uric acid and urine pH- could be a driver of PKD disease progression.
A practical approach to panel design, validation, and interpretation for the evaluation of T ‐cell neoplasms by flow cytometry
Oak, Jean , Furtado, Felipe Magalhaes, Devitt, Katherine , Fromm, Jonathan R. , Qiu, Lianqun , Illingworth, Andrea , Cardinali, Jolene, Devitt, Katherine A , Qiu, Lianqun , Horna, Pedro , Kern, Wolfgang , Al-Attar, A , Shi, Min

Mayo Clinic

Cytometry Part B: Clinical Cytometry | October 22, 2025 | Volume: 108 | Issue: 6 | Pages: 430-447

10.1002/cyto.b.22258 | PMID 41122063 Get It

Abstract The diagnosis of T‐cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T‐cell neoplasms. We outline the utility of key antigens in the screening and classification of T‐cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the “difference from normal” method and template‐based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating these principles into laboratory workflows, this manuscript aims to standardize and improve the assessment of T‐cell neoplasms across diverse clinical settings.
Who Shapes the Future of Health Communication? Networks, Silos, and New Imperatives in the Digital Age
Britt, Rebecca K. , Franco, Courtny L. , Sams, Amanda, Ginwal, Priyanka , Obregón, Rafael , Ratzan, Scott C. , Ivic, Rebecca K , Franco, Courtny, Rubinelli, Sara , Sams, Amanda

Mayo Clinic

Journal of Health Communication | October 22, 2025 | Volume: 30 | Issue: 10-12 | Pages: 522-527

10.1080/10810730.2025.2574675 | PMID 41121593 Get It

Artificial Intelligence for Patient Education: A Primer, Not a Proxy
D’Souza, Ryan S. , Benzon, Honorio T., D'Souza, Ryan S , Benzon, Honorio T. , Nelson, Ariana M.

Mayo Clinic

A&A Practice | October 21, 2025 | Volume: 19 | Issue: 10 | Pages: e02071

10.1213/xaa.0000000000002071 | PMID 41118602 Get It

Tau biology, biomarkers, and therapeutics
Kolb, Hartmuth C. , DeVos, Sarah L. , Edelmayer, Rebecca M. , Elwood, Fiona , Fleisher, Adam , Henley, David , Kreisl, William Charles, Kulic, Luka , Leuzy, Antoine , Parmentier‐Batteur, Sophie, Patru, Maria‐Magdalena, Rabinovici, Gil D. , Reyderman, Larisa, Geyten, Serge Van der , Wildsmith, Kristin R., Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Rabinovici, Gil D , Frost, Bess , Algeciras‐Schimnich, Alicia , Betthauser, Tobey J. , Horie, Kanta , Hyman, Bradley T. , Palma, Jose-Alberto , Sperling, Reisa Anne , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | October 21, 2025 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/trc2.70165 | PMID 41126950 Get It

Abstract As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. The Fall 2024 Alzheimer's Association Research Roundtable convened experts from academia, industry, National Institutes of Health (NIH), and the United States Food and Drug Administration (FDA) to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Discussions addressed the integration of tau biomarkers into the 2024 Revised Diagnostic Criteria for AD, updates to amyloid and tau positron emission tomography (PET) imaging, and modeling of biomarker trajectories. Presenters highlighted tau‐targeting therapeutics including antisense oligonucleotides, monoclonal antibodies, and small molecules, alongside innovations in drug delivery. The interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials were key themes. Regulatory insights facilitated discussions on drug approval pathways. The meeting highlighted the rapid evolution of tau research and emphasized opportunities to improve diagnostics, trial design, and treatment strategies in AD. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. Discussions addressed the integration of tau biomarkers into the 2024 revised diagnostic criteria for AD, updates to amyloid and tau PET imaging, modeling of biomarker trajectories, tau‐targeting therapeutics, and interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials.
Demystifying machine learning in endourology – understanding models, applications, and clinical impact: a review from EAU endourology
Ghnatios, Chady , Panthier, Frédéric , Attieh, Rose Mary

Mayo Clinic

Current Opinion in Urology | October 21, 2025 | Volume: 36 | Issue: 1 | Pages: 66-71

10.1097/mou.0000000000001348 | PMID 41117525 Get It

Purpose of review Machine learning algorithms are occupying a larger space in medical and urology applications. However, typical medical physicians are not trained on these technologies and do not master the possibilities offered by these tools, to imagine their applications in the medical field. This manuscript is indented to be a guide in the use of machine learning in different urology applications, and to demystify the available machine learning and artificial intelligence algorithms. This manuscript reviews some of their applications and potential applications to the medical and urology field. Recent findings Multiple works are published on the use of machine learning in urology, with performance demonstrated to be noninferior to human experts on multiple occasions. However, the major part of the machine learning publications in urology applications are concentrated on diagnosis and/or prognosis. Advanced machine learning algorithms based on agentic artificial intelligence, able to perform decisions and causality-based treatment optimization, are rarely put to use in urology. The democratization of advanced machine learning technologies in the medical fields can accelerate the adoption of these techniques, and potentially improve the patient care through relevant suggestive decision making. Summary This work aims to demystify the machine learning tools for medical applications, facilitate decision making and adoption of the correct tools for the correct applications, and places a roadmap for the future of machine learning in the enhancement of patient care in urology.
Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?
Datta, Soumyadeep , Litzow, Mark R.

Mayo Clinic

Blood Advances | October 20, 2025 | Volume: 10 | Issue: 4 | Pages: 999-1011

10.1182/bloodadvances.2025015936 | PMID 41115238 Get It

Abstract Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells. Despite advances in chemotherapy, a significant proportion of patients continue to have poor outcomes. Immunotherapy has emerged as a transformative approach in the treatment of ALL, offering new hope for these patients. This advances viewpoint article provides a comprehensive overview of the role of immunotherapy in ALL, focusing on the mechanisms of action, the timing of its use, the patient populations most likely to benefit, and drug resistance. We discussed the major immunotherapeutic modalities, including monoclonal antibodies, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapy. We review key clinical trials that have shaped the current landscape of immunotherapy in B-cell precursor (BCP)–ALL, along with future directions in this rapidly evolving field and discussed our perspective on how best to exploit the use of immunotherapy for patients with newly diagnosed adult BCP-ALL.
Prevalence of Cannabidiol (CBD) Use in an Outpatient Hand Surgery Clinic
Deckey, David G. , Ishimoto, A., Renfree, Sean P. , Noland, Shelley S. , Iturregui, Jose M. , Ishimoto, Alyssa, Renfree, Kevin J.

Mayo Clinic

Orthopedics | October 20, 2025 | Volume: 48 | Issue: 6 | Pages: 329-335

10.3928/01477447-20250904-01 | PMID 41114690 Get It

Background: The aim of this study was to evaluate the prevalence and perceived efficacy of cannabidiol (CBD) products in patients presenting to an orthopedic hand and upper extremity clinic. Materials and Methods: New patients seen for an initial surgical consultation between July and December 2022 were surveyed regarding CBD use, pain, and function. Pain was measured with the Numeric Pain Rating Scale (NPRS, 0–10) and function with the Single Assessment Numeric Evaluation (SANE, 0–100). Demographic and clinical factors were collected via chart review. Results: A total of 918 patients completed the survey (53% female; mean age 63 years, range 18–97). Joints involved included elbows (106), wrists (335), and hands/fingers (667). Common diagnoses included arthritis (199), tendinopathy (273), and nerve-related conditions (160). Overall, 15% (135/918) reported prior CBD use, and 39% (53/135) perceived pain relief. CBD users were more likely to be female (65% vs 51%; P =0.003), to present with wrist pathology (44% vs 35%; P =0.038), and to have arthritis (36% vs 19%; P <0.001). Compared to non-users, CBD users reported higher pain scores (mean NPRS 6.2 vs 5.1; P <0.001) and lower contralateral function (mean SANE 77.3 vs 87.4; P <0.001). Conclusions In this cohort, CBD use was uncommon, and only a minority of users reported subjective benefit. CBD users tended to report higher pain and worse function, particularly in the setting of wrist arthritis. CBD products did not appear to provide measurable objective improvement in pain or function. Further studies are needed to clarify optimal dosing, administration, and potential role in upper extremity care.
Acute Severe Ulcerative Colitis (ASUC): Clinical Features, Initial Management, and the Role of Advanced Therapies
Jamal, Fares , Ivanov, Marina, Elmasry, Sandra , Gonzalez, Alejandro, Malik, Talha A. , Gonzalez, Alejandro J , Malik, Talha A. , Jamal, Fares

Mayo Clinic

Biomedicines | October 20, 2025 | Volume: 13 | Issue: 10 | Pages: 2544

10.3390/biomedicines13102544 | PMID 41153824 Get It

Acute severe ulcerative colitis (ASUC) is a medical emergency affecting up to 25% of patients with ulcerative colitis (UC), with colectomy required in approximately 25–30% of cases during the initial admission. Intravenous corticosteroids remain the first-line therapy, though one-third of patients do not respond, necessitating rescue with infliximab or calcineurin inhibitors, which are both supported by randomized trials and guideline recommendations. Comparative studies and meta-analyses have shown similar efficacy between these agents, while sequential use is associated with higher adverse event rates and should be restricted to specialized centers. Recent data have refined infliximab use, with the PREDICT-UC trial showing no superiority of intensified dosing over standard regimens. Emerging therapies are under investigation: vedolizumab has been used as maintenance following calcineurin induction; ustekinumab has shown benefits in retrospective UC cohorts, particularly after cyclosporine; and Janus kinase (JAK) inhibitors represent the most recent addition. The randomized TACOS trial and the prospective TRIUMPH study demonstrated an improved short-term response with tofacitinib in steroid-refractory ASUC, and real-world reports suggest promising outcomes with upadacitinib. While infliximab and cyclosporine remain as standard rescue therapies, ongoing trials with novel agents are likely to broaden treatment options. This review summarizes the clinical features, initial management, and the role of advanced therapies in ASUC.